{"filings":[{"id":780477,"accession_number":"0001850902-26-000011","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2026-06-01T21:22:10+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alpha Teknova director Irene Davis to retire; board reduced from 8 to 7; shareholder votes approved nominees and auditor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Irene Davis will not stand for re-election and retires from board effective June 1, 2026, due to personal interests, not disagreement.","Board reduced from 8 to 7 directors and Class II from 3 to 2, effective June 1, 2026.","Ms. Demski appointed to Nominating and Corporate Governance Committee effective June 1, 2026.","At annual meeting, J. Matthew Mackowski and Brett Robertson elected as Class II directors with 43.7M and 44.0M votes for respectively.","Ratification of Grant Thornton as independent auditor for FY 2026 approved with 47,753,544 for, 2,167 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96223,"accession_number":"0001850902-26-000007","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01","5.05"],"status":"ready","headline":"Teknova Q1 revenue $11.1M (+13% YoY); reaffirms FY 2026 guidance $42-44M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.1M, up 13% YoY; Clinical Solutions revenue surged 85% to $2.1M.","Net loss $4.6M (diluted EPS -$0.08) vs $4.6M; Adjusted EBITDA improved to -$2.0M from -$2.5M.","Gross margin expanded to 34.2% from 30.7%; Free Cash Outflow improved to $3.6M from $4.3M.","Reaffirmed FY 2026 revenue guidance $42-44M and Free Cash Outflow under $10M.","Cash and short-term investments $17.8M; total borrowings $13.2M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":11077000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109924,"accession_number":"0001193125-26-076592","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova reports Q4 and FY2025 revenue growth, provides 2026 guidance of $42-44M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 total revenue $40.5M, up 7% from $37.7M in 2024.","Q4 2025 revenue $10.0M, up 8% from $9.3M in Q4 2024.","Clinical Solutions revenue up 47% in Q4 to $2.7M; 25% annual growth in Clinical Solutions customers.","Net loss improved to $17.3M in 2025 from $26.7M in 2024; Adjusted EBITDA improved to -$6.7M from -$14.5M.","Company expects 2026 revenue of $42-44M and free cash outflow less than $10M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":40520000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126504,"accession_number":"0001193125-25-269488","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q3 revenue $10.5M (+9% YoY); net loss narrows to $4.3M; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.5M, up 9% from Q3 2024; Lab Essentials $8.3M (+16%), Clinical Solutions $1.7M (-13%).","Gross margin 30.7% vs 0.9% (Q3 2024); prior year included $2.8M non-recurring inventory charges.","Net loss $4.3M ($0.08/share) vs $7.6M ($0.15/share) a year ago; Adjusted EBITDA -$1.6M vs -$5.0M.","Free Cash Outflow $2.4M, flat YoY. Cash & short-term investments $22.1M; borrowings $13.2M.","Reaffirms FY2025 revenue guidance $39-42M and Free Cash Outflow <$12M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":30536000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143250,"accession_number":"0000950170-25-105005","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q2 revenue $10.3M (+7% YoY); net loss narrows to $3.6M; reaffirms FY25 guidance $39-42M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue of $10.3M, up 7% from $9.6M in Q2 2024.","Net loss of $3.6M ($0.07 per share) vs $5.4M ($0.13) in prior-year quarter.","Gross margin improved to 38.7% from 29.2% on manufacturing efficiency gains.","Adjusted EBITDA loss narrowed to $0.8M from $2.6M; free cash outflow $2.3M vs $3.0M.","Company reaffirms 2025 revenue guidance of $39-42M and free cash outflow <$12M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":20082000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161380,"accession_number":"0000950170-25-089004","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alpha Teknova shareholders elect Demski and Herzick as Class I directors; auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Martha J. Demski elected with 42,901,743 votes for (99.1% of votes cast, excluding broker non-votes).","Alexander Herzick elected with 42,594,414 votes for (98.3% of votes cast, excluding broker non-votes).","Ratification of Grant Thornton LLP as auditor for FY 2025 passed with 47,336,767 for, 6,200 against, 13,554 abstentions.","88.62% of outstanding shares (47,356,521) represented at the June 17, 2025 annual meeting.","Approximately 4.0 million broker non-votes did not affect the director election outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161379,"accession_number":"0000950170-25-067005","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q1 revenue up 5% to $9.8M, net loss narrows to $4.6M, guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $9.8M (+5% YoY); Lab Essentials $8.1M (+12%), Clinical Solutions $1.2M (-32%).","Net loss narrowed to $4.6M ($0.09/share) from $8.1M ($0.20/share) in Q1 2024.","Adjusted EBITDA loss improved to $2.5M from $3.8M; free cash outflow decreased to $4.3M from $6.7M.","Exclusive collaboration with Pluristyx to manufacture/distribute PluriFreeze cryopreservation system in US/Canada.","Reaffirms FY2025 revenue guidance of $39-42M and free cash outflow under $12M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":9795000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179548,"accession_number":"0000950170-25-031995","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Teknova reports FY2024 revenue $37.7M (+3% YoY), guides FY2025 $39-42M, amends credit facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $37.7M (+3% YoY); Q4 revenue $9.3M (+18% YoY). Clinical Solutions Q4 revenue $1.85M (+110% YoY).","Net loss FY2024 $26.7M ($0.57/share) vs $36.8M ($1.16) in FY2023; adjusted EBITDA -$14.5M vs -$19.8M.","2025 guidance: revenue $39-42M, free cash outflow <$12M (vs -$13.5M in FY2024).","New $28.245M credit facility ($23.245M term + $5M revolver), maturity March 2030, principal pay starting April 2028.","Covenants: minimum net revenue $39M for TTM ending Dec 2025; minimum cash $8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196272,"accession_number":"0000950170-24-123359","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q3 revenue up 17% to $9.6M; net loss $7.6M; guidance reiterates $35-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $9.6M (+17% YoY); Clinical Solutions up 229% to $2.0M; Lab Essentials flat at $7.2M.","GAAP net loss $7.6M ($0.15 EPS); adjusted EBITDA negative $5.0M; excludes $2.8M non-cash inventory charge.","Gross margin 0.9% (29.8% excluding $2.8M charge) vs 18.0% in Q3 2023.","Operating expenses down to $7.5M from $10.2M YoY, driven by reduced headcount and professional fees.","2024 free cash outflow outlook lowered to <$16M from <$18M; revenue guidance reaffirmed at $35-38M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":28480000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212557,"accession_number":"0000950170-24-096188","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova Q2 revenue $9.6M, down 17% YoY; reaffirms FY2024 guidance $35-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.6M, down 17% YoY but up 3% sequentially; Lab Essentials flat, Clinical Solutions down 57%.","Net loss $5.4M ($0.13/share) vs $7.2M prior year; Adjusted EBITDA negative $2.6M.","Gross margin fell to 29.2% from 43.9% due to lower Clinical Solutions revenue and higher overhead.","Raised $15.4M equity in July 2024; cash $18.6M, debt $12.1M; confirms free cash outflow <$18M for FY.","Clinical customers up 26% to 43; launched Express-Tek and RUO+ offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":18904000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212556,"accession_number":"0000950170-24-083216","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Alpha Teknova raises $15.4M via private placement at $1.24/share; insiders buy 12.2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 12,385,883 common shares at $1.24 each, raising ~$15.4M before expenses.","Insiders (Telegraph Hill Partners, CEO, CFO) purchased 12,217,740 shares (98.6% of offering).","Net proceeds will be used for general corporate purposes; shares are unregistered.","Company must file resale registration statement within 45 days; liquidated damages apply for delays.","Offering closed July 12, 2024; priced at Nasdaq closing price on July 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212555,"accession_number":"0000950170-24-082477","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova reports Q2 2024 rev $9.4-9.6M, reaffirms FY guidance $35-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 total revenue $9.4-9.6M, down 17-18% YoY but up 7-9% adjusting for large prior-year order.","FY 2024 revenue guidance reaffirmed at $35-38M; free cash outflow <$18M.","Headcount reduced >40% from Q2 2022 peak to 169; cash used in Q2 was $3.0-3.4M.","Clinical Solutions customers grew from 34 to 43; Lab Essentials customers from 2,829 to 2,913.","No single direct customer >$1M YTD; full Q2 results expected August 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":18904000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212554,"accession_number":"0000950170-24-079686","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alpha Teknova board member Ted Davis retires; board size reduced to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ted Davis retired from the Board on June 26, 2024, citing personal and professional interests.","Board reduced from 9 to 8 directors; Class I directors cut from 3 to 2 effective June 28.","Davis's departure not due to any disagreement with the Company or Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231563,"accession_number":"0000950170-24-078538","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alpha Teknova stockholders elect directors Grossman, Gunstream, Vos; ratify Grant Thornton","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["81.03% of shares represented at June 24, 2024 annual meeting.","Paul Grossman elected with 28,409,610 votes for, 807,568 withhold.","Stephen Gunstream elected with 28,707,652 votes for, 511,020 withhold.","Alexander Vos elected with 28,124,476 votes for, 1,094,196 withhold.","Grant Thornton LLP ratified as auditor for FY2024: 33,071,709 for, 1,650 against, 5,913 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231562,"accession_number":"0000950170-24-058639","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova Q1 revenue $9.3M (+2% YoY); net loss narrows; reaffirms FY guidance $35-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $9.3M, up 2% YoY; net loss $8.1M ($0.20 loss per share) vs $8.8M loss in Q1 2023.","Gross margin fell to 23.8% from 26.6% due to higher overhead and depreciation from new facility.","Adjusted EBITDA negative $3.8M, improved from negative $6.1M; free cash outflow $6.7M vs $12.0M.","Reaffirmed FY2024 revenue guidance $35-38M and free cash outflow less than $18M.","Launched Build-Tek custom configurator and AAV-Tek AAV Stabilizer product."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":9290000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231561,"accession_number":"0000950170-24-039576","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Alpha Teknova appoints Grant Thornton as auditor; EY flagged going concern","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit committee approved Grant Thornton as independent auditor effective March 26, 2024, replacing Ernst & Young.","EY's 2023 audit report contained an explanatory paragraph regarding the company's ability to continue as a going concern.","A material weakness in internal controls identified for 2022 was remediated as of the 2023 annual report.","No disagreements or reportable events occurred between the company and EY except the previously disclosed material weakness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249908,"accession_number":"0000950170-24-029226","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["1.01","2.02","9.01","3.02"],"status":"ready","headline":"Alpha Teknova reports FY 2023 revenue $36.7M, down 11%; guides 2024 rev $35-38M; receives covenant waiver from MidCap","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2023 revenue $36.7M, down 11% YoY; net loss $36.8M ($1.16 diluted EPS); Adjusted EBITDA -$19.2M.","Q4 2023 revenue $7.9M (flat YoY), gross margin 17.0% vs 26.7%; net loss $10.7M ($0.26 diluted EPS).","Issued warrant to MidCap for 125k shares at $2.9934; MidCap waived revenue covenant violations for Nov 2023/Jan 2024 and reduced min revenue req from $42M to $34M.","2024 revenue guidance $35-38M (assuming ~10% Lab Essentials growth); free cash outflow expected <$18M.","Board approved stock option repricing effective Mar 14, 2024 to retain employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249907,"accession_number":"0000950170-24-004716","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["2.05","5.02","9.01"],"status":"ready","headline":"Alpha Teknova cuts 15% of workforce, CCO and CPO depart; option repricing approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~15% of current employees; annualized cost savings estimated at $6.4M.","Severance and related charges of ~$1.2M expected, all cash; RIF substantially complete by Feb 1, 2024.","CCO Ken Gelhaus and CPO Lisa McCann to exit March 1; roles eliminated in restructuring.","Outstanding employee and director options repriced to fair market value on March 14, 2024; reduced exercise price effective only after Sept 14, 2025 or earlier qualifying termination.","Option repricing applies to 1,635,381 shares held by employees/directors; stockholder consent obtained Jan 16."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267396,"accession_number":"0000950170-23-062023","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q3 revenue $8.2M, down 24% YoY; net loss $10.2M; raised $22.9M equity, trimmed debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $8.2M (-24% YoY); Lab Essentials $7.3M (-23%), Clinical Solutions $0.6M (-35%).","Net loss $10.2M ($0.34/share) vs $22.5M ($0.80/share) prior year; adjusted EBITDA -$5.5M.","Gross margin fell to 18.0% from 44.6% due to lower revenue and fixed cost underabsorption.","Raised $22.9M equity capital; repaid $10.0M long-term debt; expects FY free cash outflow <$30M.","FY2023 revenue now expected at low end of $37-40M guidance range."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":28817000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284641,"accession_number":"0001193125-23-237669","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Alpha Teknova raises $22.9M in equity and amends credit facility with reduced revenue covenants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $22.9M gross via 1.1M registered-direct shares and 11.3M PIPE shares at $1.85/sh; insiders bought 9.05M shares.","Prepaid $10M of term loan principal; entered Amendment No.4 with MidCap waiving July 31, 2023 revenue covenant violation.","Minimum net revenue covenants reduced for FY2023 from $42M to $36.5M, FY2024 $49M to $42M, FY2025 $58.8M to $50M.","Minimum cash requirement reduced from $10M to $9M; exit fee increased from 8.5% to 9.0%.","Revolving loan borrowing conditioned on achieving $45M trailing twelve-month net revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284640,"accession_number":"0000950170-23-042497","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alpha Teknova appoints Martha J. Demski to Board, effective Aug 31, replacing McNamara","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martha J. Demski appointed as Class I Director until 2025 annual meeting.","She will serve as Chair of Audit Committee and on Compensation Committee.","Demski receives $40,000/yr Board cash, $20,000/yr Audit Chair, $7,500/yr Comp Committee.","Initial stock option grant of 0.2% outstanding shares, vesting over 3 years.","Demski is independent and an audit committee financial expert; no related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284639,"accession_number":"0000950170-23-041316","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q2 revenue $11.5M (+26% seq, -1% YoY); cuts 2023 revenue guidance to $37-40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.5M, up 26% sequentially but down 1% YoY; net loss $7.2M ($0.25/share).","Clinical Solutions revenue grew 24% YoY to $3.7M; Lab Essentials fell 10% to $7.6M.","Company reduces 2023 revenue guidance to $37-40M from prior; maintains free cash outflow ~$30M.","Received certification for new GMP production facility, expanding capacity to $200M.","Adjusted EBITDA improved to -$2.3M from -$4.9M; non-cash impairment charge of $2.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":20648000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284638,"accession_number":"0000950170-23-032403","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alpha Teknova director Robert McNamara resigns from Board effective Aug 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McNamara cited personal and professional commitments; no disagreement with the Board or Company.","He served as Chairman of the Audit Committee and member of the Compensation Committee.","Resignation effective August 31, 2023; no replacement named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304370,"accession_number":"0000950170-23-028767","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alpha Teknova shareholders elect Class II directors and ratify Ernst & Young as auditor for FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["92.61% of outstanding shares (26,108,719) represented at the 2023 Annual Meeting.","Irene Davis, J. Matthew Mackowski, and Brett Robertson elected as Class II directors; each received >21.6M votes for.","Ernst & Young LLP ratified as independent auditor for fiscal 2023 with 26,093,103 votes for, 14,484 against.","Broker non-votes on director election totaled 2,408,192; no other proposals were contested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304369,"accession_number":"0000950170-23-020499","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q1 revenue $9.1M, down 18% YoY; net loss $8.8M; reaffirms FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $9.1M, up 16% sequentially but down 18% from $11.1M in Q1 2022.","Net loss $8.8M ($0.31 per diluted share) vs $5.5M loss in Q1 2022; adjusted EBITDA -$6.1M.","Gross margin fell to 26.6% from 48.0% due to lower revenue and fixed cost absorption.","Reaffirmed FY2023 revenue guidance $42-46M and free cash outflow ~$30M.","Launched proprietary AAV-Tek Solutions product line; GMP facility qualification underway toward mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":9121000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.68,"calibrated_materiality_score":0.68,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323992,"accession_number":"0000950170-23-008125","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova reports FY22 revenue $41.4M (+12% YoY); net loss $47.5M; guides FY23 rev $42-46M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year revenue $41.4M, up 12% YoY; Q4 revenue $7.9M, down 22% YoY.","Net loss for FY22 was $47.5M ($1.69/share) vs $9.8M in FY21.","Goodwill and long-lived asset impairment charges of $20.8M (non-cash).","FY23 revenue guidance $42-46M; expects ~$30M free cash outflow.","New manufacturing facility is operational; GMP production expected by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323991,"accession_number":"0000950170-23-007388","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Alpha Teknova confirms no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company states it holds no cash deposits or securities at Silicon Valley Bank.","No business relationship exists with SVB, per March 10, 2023 disclosure.","Update comes as SVB faced liquidity crisis and was seized by regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341963,"accession_number":"0000950170-22-023843","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova Q3 revenue up 14% to $10.7M, net loss widens on $16.6M goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.7M (+14% YoY); Lab Essentials $9.47M (+32%).","Net loss $22.5M ($0.80 loss per share) vs loss $3.3M in Q3 2021; includes $16.6M non-cash goodwill impairment.","Adjusted EBITDA -$4.6M vs -$2.7M; Free Cash Flow -$14.9M.","FY2022 revenue guidance lowered to $40-42M (midpoint ~16% growth excl. Sample Transport).","Cash $49.9M; new facility qualification underway, research-grade production expected by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":33529000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358797,"accession_number":"0000950170-22-016447","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova reports Q2 2022 revenue of $11.7M, up 41% YoY, updates 2022 outlook to $38-42M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue reached $11.7 million, a 41% increase from $8.3 million in Q2 2021.","Net loss for Q2 2022 was $6.2 million ($0.22 per diluted share), compared to net loss of $2.3 million ($0.52 per share) in Q2 2021.","Adjusted EBITDA was negative $4.9 million in Q2 2022, versus negative $1.5 million in Q2 2021.","Cash position of $64.7 million; company updates 2022 revenue guidance to $38-$42 million, implying ~13% mid-point growth excluding Sample Transport.","CEO cited lower-than-expected H2 revenue due to early-stage biopharma customers deferring large purchases."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":22837000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377550,"accession_number":"0000950170-22-011174","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alpha Teknova stockholders elect three Class I directors and ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Ted Davis, Alexander Herzick, and Robert McNamara as Class I directors through 2025.","Each director received >22.9 million votes for; broker non-votes were 838,180.","Ratification of Ernst & Young as independent auditor for FY 2022 passed with 27,752,280 votes for, 57 against.","Meeting had 27,752,359 shares represented, 98.96% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377549,"accession_number":"0001193125-22-146645","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["1.01","2.03","3.03","9.01"],"status":"ready","headline":"Alpha Teknova expands credit facility to $57.135M via amended MidCap term loan and revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $57.135M facility comprises $52.135M senior secured term loan and $5M revolver (up from $27M).","Term loan funded in stages: $5.135M immediately, $5M on Oct 31 2022, plus additional tranches through Jan 2024 subject to revenue and liquidity milestones.","Interest on term loan at one-month LIBOR + 6.45% (1% floor); revolver at LIBOR + 3.75% (1% floor); maturity May 1, 2027.","Facility restricts dividends and distributions; contains a trailing 12-month revenue covenant of $42.5M by Dec 31, 2022.","Exit fee of $0.6M (5% of original $12M draw) due at maturity; prepayment penalties of 3%-1% apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377548,"accession_number":"0000950170-22-009317","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q1 revenue $11.1M (+23% YoY); guides FY2022 revenue $45-48M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2022 revenue $11.1M up 23% YoY; Lab Essentials $6.98M, Clinical Solutions $3.81M, Sample Transport $6K.","Net loss -$5.5M (-$0.20 diluted EPS) vs -$0.7M loss in Q1 2021; Adjusted EBITDA -$4.3M vs break-even.","Cash position $76.5M; amended credit facility increased from $27M to $57M to fund growth.","FY2022 revenue guidance of $45-48M (over 30% growth at midpoint); Lab Essentials ~25% growth, Clinical Solutions at least 60%.","No material Sample Transport revenue expected in 2022; new manufacturing facility expected online by year end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":11147000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395924,"accession_number":"0001193125-22-076043","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova FY2021 revenue $36.9M (+18% YoY); net loss $9.8M vs $0.6M income in 2020","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 total revenue $36.9M, up 18% YoY; ex-Sample Transport $35.4M, up 31% YoY.","Q4 2021 total revenue $10.1M flat; ex-Sample Transport $9.6M, up 26% YoY.","FY2021 net loss $9.8M ($0.61 loss/diluted share) vs net income $0.6M ($0.16 EPS) in 2020.","Q4 2021 net loss $3.6M ($0.13 loss/diluted share) vs net income $0.1M ($0.03 EPS) in Q4 2020.","2022 revenue guidance $44-$48M; expects 25% growth in Lab Essentials, 60% in Clinical Solutions; no Sample Transport."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414828,"accession_number":"0001193125-21-329872","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Teknova appoints Ken Gelhaus as CCO and Jennifer Henry as SVP Marketing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Gelhaus appointed CCO effective Nov 15, 2021; base salary $377,500 plus 40% bonus and 85,000 stock option.","Jennifer Henry appointed SVP Marketing; previously Senior Director of Global Brand at eBay and roles at Apple, Google, Facebook.","Gelhaus brings 15+ years life sciences experience, most recently VP/GM at BD Biosciences; Henry brings consumer brand expertise.","CCO role includes leading sales, product management, commercial operations, and customer service teams."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414827,"accession_number":"0001193125-21-325979","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q3 2021 revenue up 5% to $9.4M; net loss of $3.3M vs. prior-year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $9.4M (+5% YoY); excluding Sample Transport, revenue $9.3M (+26% YoY).","Net loss attributable to common stockholders of $3.3M ($0.12 per share) vs. net income of $0.3M ($0.07) in Q3 2020.","Gross margin fell to 45.4% from 56.6% due to capacity investments; operating expenses rose to $8.2M from $2.9M.","Cash and cash equivalents $98.0M at Sep 30, 2021; Adjusted EBITDA negative $2.7M vs. positive $2.7M in Q3 2020.","Appointed Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as SVP of Marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":26783000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432901,"accession_number":"0001193125-21-243358","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova Q2 2021 revenue up 38% to $8.3M; net loss of $2.3M vs prior-year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.3M, +38% YoY; Lab Essentials revenue $6.5M (+46%), Clinical Solutions $1.6M (+32%).","Gross margin fell to 40.4% from 57.4%; cost of sales included $0.7M one-time reserve for excess Sample Transport inventory.","Net loss attributable to common stockholders $2.3M ($0.52/share) vs net income of $0.1M ($0.02/share) in Q2 2020.","Adjusted EBITDA negative $1.5M vs positive $1.2M a year ago; cash position $108M after $99.1M IPO net proceeds.","Began construction on new GMP facility in Hollister, CA; appointed three new independent directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":17391000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":230593938.729,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}